Cell & Gene Therapy

Key capabilities

Accurately Quantify % Full Capsids in Real Time:

Gator BLI’s AAV Ratio Kit enables precise, label-free measurement of encapsulated ssDNA, detecting 5–100% full capsids.

Genome Titer and Integrity, Even in Crude Samples:

The new Genome Titer Kit delivers fast, sequence-specific quantitation from E9–E14 genomes/mL, no purification required.

Simplify and Accelerate AAV Analytics:

Skip PCR, ultracentrifugation, and ELISA—Gator BLI provides a scalable, low-CV solution for high-confidence gene therapy QC.

resources

An easy way to obtain AAV Empty/Full Ratio Analysis is the holy grail of gene therapy research. If researchers cannot identify the percentage of capsids that contain the genome of interest (% full), it’s very difficult to optimize expression to optimize and improve infectious titer. The presence of a high number of empty capsids can significantly impact the efficacy, immunogenicity, and safety of gene therapies, as only full particles are capable of delivering the therapeutic payload to target cells. For gene therapy developers and biomanufacturing teams, accurately assessing the empty/full ratio ensures that the final product is both potent and safe, meeting regulatory and therapeutic requirements.

For many users, PCR requires too much prep and takes too long to get results. Moreover, the %CV from PCR coupled with a high %CV capsid titer measurement form ELISA can make it hard to get the answers you’re looking for. Meanwhile, ultracentrifugation is costly and difficult to scale, SecMALS and mass photometry requires purified samples and don’t provide genome integrity information, just a general idea of DNA content. This makes it difficult to achieve precise measurements of viral vector quality in upstream development or to monitor the process during AAV production.

Gator Bio’s bio-layer interferometry (BLI) technology offers a label-free, real-time solution for AAV Empty/Full Ratio Analysis using its proprietary AAV Ratio Kit. With Gator BLI, researchers can quantitate total encapsulated single-stranded DNA (ssDNA) and compare it against a standard curve from similar viral samples to obtain an accurate readout of encapsulated DNA. This protocol can measure from 100%-5% full, and discriminate small differences in ssDNA in the samples with straightforward analysis. This level of precision monitoring of AAV production and ensures that the final product contains a high proportion of full viral particles, essential for therapeutic success.

Gator Bio also has a brand-new Genome titer kit, capable of measuring sequence specific titer and genome integrity in record time. With accurate genome titer from 1E¹⁰-1E¹² genomes/ml in crude samples, you can measure any genome from any gene therapy or LNP vector with confidence. Moreover, its innovative design enables this readout even in crude samples, making upstream genome integrity analytics a reality.

Key capabilities

Real-Time Kinetics for CAR, Fab, and Nanobody Binders:

Gator BLI enables label-free affinity and kinetics analysis on LNP or liposome surfaces—essential for modern CAR-T workflows.

Bypass Bottlenecks in LNP and CAR Validation:

Skip ELISA and flow cytometry with a streamlined, low-volume solution for binding analysis using crude or purified samples.

Accelerate CAR-T Engineering from Bench to IND:

Gator’s flexible, high-throughput platform supports rapid validation of CAR constructs and LNP-targeted delivery systems.flows.

resources

Chimeric Antigen Receptor T-cell (CAR-T) therapy is a transformative approach in immuno-oncology that harnesses engineered T cells to precisely target and destroy cancer cells. Accurate binder screening, affinity profiling, and functional validation of CAR constructs are critical steps in the development process. Modern CAR-T research often involves using Lipid Nanoparticles (LNPs) conjugated to Fabs in order to target LNP binding for CAR delivery. For any researchers studying CAR-T therapeutics, having a way to accurately measure kinetics of CAR, Fab, and/or nanobody proteins is a must-have, and being able to do so on a liposome surface with accuracy is essential. 

Traditional workflows in CAR-T research often rely on ELISAs or flow cytometry for CAR binder assessment, which can be time-consuming and hands-on. Optimizing LNP surface conjugation and measuring binding kinetics on the surface of LNPs is anything but simple. 

Gator Bio’s bio-layer interferometry (BLI) instruments provide a real-time, high-resolution platform to rapidly screen and characterize CAR-T binding interactions with minimal sample requirements. Our systems eliminate the bottlenecks of traditional assays by offering label-free kinetic analysis, precise affinity measurement, and streamlined workflows compatible with crude samples. Designed for flexibility, Gator Bio instruments support high-throughput screening and are ideal for labs working on T cell receptor engineering or multi-targeted CARs. With intuitive software and reliable hardware, researchers can generate publication- and IND-ready data in less time, accelerating innovation from discovery to clinical translation.

Key capabilities

Fast, Real-Time Antigen-Antibody Characterization:

Gator BLI provides label-free binding and kinetics data for mAbs, viral proteins, and vaccine antigens, even from crude or complex samples.

Accelerate Discovery Across Vaccine Platforms:

Quickly screen and validate candidates across mRNA, recombinant protein, and VLP formats with minimal sample prep.

Improve Reproducibility and Reduce Assay Time:

Gator’s automated, high-throughput BLI enables reproducible insights into epitope specificity and immunogenicity—without the ELISA bottleneck.

resources

Next-gen vaccine Development is a critical focus for both biopharma companies and academic research labs working in immunotherapy, infectious disease, and synthetic biology. Vaccine candidates need to cause an immune response in their target, so optimizing the expression of target antigens on their surface, verifying host receptor interaction, and measuring neutralizing antibodies after immunization are all critical steps in the process of evaluating potency and mechanism of action. Moreover, epitope specificity plays an even more important role, and tailoring antigen presentation to ensure antibody expression specific to critical protein domains can dramatically improve patient outcomes. With the rise of mRNA platforms, recombinant proteins, and virus-like particles, there’s an increased need for techniques that can handle complex formats and evolving modalities. As nations transition to developing pandemic-preparedness programs to combat tomorrow’s biological threats, the need for sensitive tools for studying vaccine biophysics grows greater by the day.

Traditional workflows for vaccine characterization often involve time-consuming titration ELISAs, limited-throughput plate assays, or roadblocks to kinetic characterization on LNPs that reduce data reproducibility. These methods struggle to deliver real-time insights or require high sample volumes and extensive purification steps. 

Gator Bio’s bio-layer interferometry (BLI) systems streamline vaccine candidate screening by enabling label-free, real-time binding assays with minimal sample consumption. Whether you’re analyzing monoclonal antibody binding to viral proteins or monitoring antigen-antibody interactions across candidate libraries, Gator BLI delivers high-throughput kinetic data in hours, not days. Unlike older platforms, Gator’s BLI instruments are optimized for low sample volumes, crude samples, and automated workflows, reducing assay time and human error. With support for multiplex formats and complex biotherapeutics, Gator Bio empowers teams to accelerate decision-making and improve reproducibility in vaccine development.

Key capabilities

Real-Time, Label-Free Viral Particle Quantification:

Gator BLI enables fast, sensitive titering of AAV, adenovirus, and lentivirus vectors directly from crude samples—no purification needed.

Supports E9–E10 VP/mL Detection with High Precision:

Measure viral capsid concentration at key stages of development, QC, or process optimization with low %CV and high reproducibility.

Optimize Yield and Target Binding Simultaneously:

Gator BLI also lets you evaluate capsid-target interactions, streamlining upstream optimization and empty/full ratio analysis.

resources

Just like quantitation of antibodies, peptides, and other proteins, any researcher needs a fast, reliable way to measure how much of their product they’ve made. Viral vector titer determination is a critical step in the development and manufacturing of gene therapies, including those utilizing AAV (adeno-associated virus), adenovirus, and lentivirus vectors. Accurately quantifying the viral vector titer is essential for ensuring the right dose in upstream development, preclinical studies, clinical trials, biomanufacturing, QC, stability testing, and every other stage of development. Moreover, having access to the number of viral capsid, rather than infectious titer, can be paired with any other genome titering method (like PCR, AUC, or SEC-MALS) to obtain an empty/full ratio and understand how to optimize the expression of not just genomes, but intact and loaded capsids. 

Traditional viral titer assays often rely on methods like plaque assays, ELISA, or qPCR, which can be time-consuming, labor-intensive, and lack consistency, with poor %CVs that limit the reliability of your data. 

Gator Bio’s bio-layer interferometry (BLI) technology offers a robust, label-free, real-time solution for measuring viral vector titers, including AAV, adenovirus, and lentivirus. Gator BLI can detect viral particles with remarkable sensitivity in many crude matrices, quantifying viral concentrations down to 10⁹-10¹⁰ viral particles per milliliter for most viruses. With Gator BLI, you can monitor viral load during vector production and optimize upstream processes to ensure consistent, high-quality vector product.Gator BLI can also be used to observe how well viral capsids bind to their targets, allowing researchers to optimize target binding. With Gator’s high-throughput capabilities and minimal sample requirements (as low as 40 ul/sample), Gator Bio’s platform accelerates viral vector quantification, improving efficiency and data reliability in both research and manufacturing environments.